Business
Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings
Expert panel establishes structured approach to tardive dyskinesia screening, diagnosis and treatment in long-term care, including use of VMAT2 inhibitorsNew
About this update from Neurocrine Biosciences, Inc.
[{"type":"text","content":"Expert panel establishes structured approach to tardive dyskinesia screening, diagnosis and treatment in long-term care, including use of VMAT2 inhibitorsNew post-hoc KINECT‑PRO™ analysis in adults aged 65 years and older demonstrates clinically meaningful patient-reported improvements in tardive dyskinesia impact with INGREZZA® (valbenazine) capsules, reinforcing expert panel recommendationsSAN DIEGO, March 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of the first expert consensus recommendations focused on screening, diagnosis and treatment of tardive dyskinesia among older adults in long-term care settings. Developed through a multidisciplinary Delphi panel, the recommendations address persistent gaps in recognizing and managing tardive dyskinesia in this higher-risk population. Findings were presented at the Society for Post-Acute and Long-Term Care Medical Association (PALTmed) PALTC26 Annual Conference in Anaheim, Calif.\n \n \n \n \n \n \n \nThe company also presented a first-of-its-kind post-hoc analysis from the KINECT‑PRO™ study demonstrating meaningful improvements in patient‑reported tardive dyskinesia (TD) impact among adults aged 65 years and older treated with INGREZZA® (valbenazine) capsules. This analysis adds to the growing body of evidence supporting the appropriateness, efficacy, tolerability and established safety profile of INGREZZA in this patient population.\"To date, there has been limited practical guidance tailored specifically to the screening, diagnosis and treatment of tardive dyskinesia in the long-term care setting,\" said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. \"The consensus recommendations provide structured guidance for clinicians caring for residents in these environments, and the KINECT-PRO findings demonstrate clinically meaningful patient-reported improvements in the impact of tardive dyskinesia with INGREZZA in adults aged 65 years and older. Together, this guidance and evidence help support more informed treatment decisions in this population that may be at higher risk for tardive dyskinesia.\"Older adults in long-term care are at an elevated risk for TD due to prolonged exposure to dopamine receptor blocking agents, advanced age, polypharmacy and complex comorbidities. Recognition and management may b...